Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids

Contact Dermatitis

Volumn 70, Issue 3, 2014, Pages 158-168

  Cortesi, Paolo A ^a,b   Scalone, Luciana ^a,b   Belisari, Andrea ^b   Bonamonte, Domenico ^c   Cannavò, Serafinella Patrizia ^d   Cristaudo, Antonio ^e   De Pità, Ornella ^f   Gallo, Rosella ^g   Giannetti, Alberto ^h   Gola, Massimo ⁱ   Pigatto, Paolo D ^j   Mantovani, Lorenzo G ^b,k  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Fondazione Charta   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^f LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j UNIVERSITY OF MILAN   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

more..

Author keywords

chronic hand eczema; cost of illness; health related quality of life; healthcare costs; loss of productivity; refractoriness to therapy

Indexed keywords

CORTICOSTEROID;

ADULT; AGED; ALGORITHM; ARTICLE; CORTICOSTEROID THERAPY; COST OF ILLNESS; DERMATOLOGY LIFE QUALITY INDEX; FEMALE; HAND ECZEMA; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; QUALITY OF LIFE; SOCIOECONOMICS; TOPICAL DRUG ADMINISTRATION; TREATMENT DURATION; VERY ELDERLY; YOUNG ADULT;

CHRONIC HAND ECZEMA; COST OF ILLNESS; HEALTH-RELATED QUALITY OF LIFE; HEALTHCARE COSTS; LOSS OF PRODUCTIVITY; REFRACTORINESS TO THERAPY;

ABSENTEEISM; ACTIVITIES OF DAILY LIVING; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COST OF ILLNESS; DIRECT SERVICE COSTS; ECZEMA; EFFICIENCY; FEMALE; HAND DERMATOSES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84896735976     PISSN: 01051873     EISSN: 16000536     Source Type: Journal    
DOI: 10.1111/cod.12130     Document Type: Article

References (38)

1. Smith H A, Burdorf A, Coenraads P J,. Prevalence of hand dermatitis in different occupations. Int J Epidemiol 1993: 22: 288-293.
2. Dickel H, Bruckner T, Berhard-Klimt C, Koch T, Scheidt R, Diepgen T L,. Surveillance scheme for occupational skin disease in the Saarland, FRG: first report from BKH-S. Contact Dermatitis 2002: 46: 197-206.
3. Diepgen T L, Agner T, Aberer W, Berth-Jones J, Cambazard F, Elsner P, McFadden J, Coenraads P J,. Management of chronic hand eczema. Contact Dermatitis 2007: 57: 203-210.
4. Apfelbacher C J, Akst W, Molin S, et al. CARPE: a registry project of the German Dermatological Society (DDG) for the characterization and care of chronic hand eczema. J Dtsch Dermatol Ges 2011: 9: 682-688.
5. Ruzicka T, Lynde C W, Jemec G B E, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008: 158: 808-817.
6. Schmitt-Hoffmann A H, Roos B, Sauer J, Spickerma J,. Pharmacokinetics, efficacy and safety of alitretinoin in moderate or severe chronic hand eczema. Clin Exp Dermatol 2011: 36 (Suppl. 2): 29-34.
7. Dirschka T, Reich K, Bissonnette R, Maares J, Brown T, Diepgen T L,. An open-label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids. Clin Exp Dermatol 2011: 36: 149-154.
8. McCall B P, Horwitz I B, Feldman S R, Balkrishnan R,. Incidence rates, costs, severity, and work-related factors of occupational dermatitis: a workers' compensation analysis of Oregon, 1990-1997. Arch Dermatol 2005: 141: 713-718.
9. Meding B, Wrangsjö K, Jarvholm B,. Fifteen-year follow-up of hand eczema: persistence and consequences. Br J Dermatol 2005: 152: 975-980.
10. Augustin M, Kussner D, Purwins S, Hieke K, Posthumus J, Diepegen T L,. Cost-of-illness of patients with chronic hand eczema in routine care: results from a multicenter study in Germany. Br J Dermatol 2011: 165: 845-851.
11. Basra M K A, Chowdhury M M U, Smith E V, Freemantle N, Piguet V,. Quality of life in psoriasis and chronic hand eczema: the discrepancy in the definition of severity in NICE guidelines and its implications. Br J Dermatol 2012: 166: 462-463.
12. Cvetkovski R S, Rothman K J, Olsen J, Mathiesen B, Iversen L, Johansen J D, Agner T,. Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. Br J Dermatol 2005: 152: 93-98.
13. Rodgers M, Griffin S, Paulden M, Slack R, Duffy S, Ingram J R, Woolacott N, Sculpher M,. Alitretinoin for severe chronic hand eczema: a nice single technology appraisal. Pharmacoeconomics 2010: 28: 351-362.
14. Agner T, Andersen K E, Brandao F M, et al. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis 2008: 59: 43-47.
15. NICE. NICE technology appraisal guidance 177, 2012. Available at: http://guidance.nice.org.uk/TA177 (last accessed 20 January 2013).
16. Drummond M, Sculpher M J, Torrance G W, O'Brien B J, Stoddart G L,. Methods for the Economic Evaluation of Health Care Programmes, 3rd edition: Oxford, Oxford University Press, 2005.
17. Cortesi P A, Scalone L, De Pità O, et al. Prevalence and cost of severe chronic hand eczema refractory to topical potent corticosteroids. Value Health 2011: 14: A490.
18. Coenraads P J, Van Der Walle H, Thestrup-Pedersen K, et al. Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis. Br J Dermatol 2005: 152: 296-301.
19. World Medical Association (WMA). WMA declaration of Helsinki. In: Adopted by the 18th WMA General Assembly, Held in Helsinki in June 1964. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html (last accessed 31 October 2012).
20. Sehgal V N, Srivastava G, Ashok K, Aggarwal A K, Sharma A D,. Hand dermatitis/eczema: current management strategy. J Dermatol 2010: 37: 593-610.
21. AIFA-Italian Medicine Agency. Available at: http://farmaco. agenziafarmacoit/index.php (last accessed 31 October 2012).
22. AGENAS. Tariffari regionali delle prestazioni di assistenza ospedaliera provided under the hospitalization and day-hospital. Available at: http://www.agenas.it/monitoraggio-costi-tariffe/monitoraggio-costi-tariffe-osp- acuti-riabilitazione.htm (last accessed 31 October 2012).
23. AGENAS. The regional 'Nomenclatore Tariffario Regionale' for outpatient costs. Available at: http://www.agenas.it/monitoraggio-costi-tariffe/ monitoraggio-costi-tariffe-prestazioni.htm (last accessed 31 October 2012).
24. Van Roijen L, Essink-Bot M L, Koopmanschap M A, Bonsel G, Ritten F F,. Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care 1996: 12: 405-415.
25. ISTAT-Italian National Institute of Statistics. Available at: http://dati.istat.it/Index.aspx (last accessed 31 October 2012).
26. Brooks R,. Euroqol: the current state of play. Health Policy 1996: 37: 53-72.
27. Baranzoni N, Scalone L, Mantovani L G, de Portu S, Monzini M S, Giannetti A,. Validation of the Italian version of the Dermatology Life Quality Index. G Ital Dermatol Venereol 2007: 142: 209-214.
28. Lewis V, Finlay A Y,. 10 Years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004: 9: 169-180.
29. Stamuli E,. Health outcomes in economic evaluation: who should value health? Br Med Bull 2011: 97: 197-210.
30. Bingeford K, Lindberg M, Isacson D,. Quality of life of topical medications and socio-economic data in hand eczema: a Swedish nationwide survey. Acta Derm Venereol 2011: 91: 452-458.
31. Deudén E, Griffiths C E, Ortonne J P, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009: 23: 1374-1382.
32. Moberg C, Alderling M, Meding B,. Hand eczema and quality of life: a population-based study. Br J Dermatol 2009: 161: 397-403.
33. Kind P, Dolan P, Gudex C, Williams A,. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998: 316: 736-741.
34. Dolan P,. Modelling valuations for EuroQol health states. Med Care 1997: 35: 1095-1108.
35. Badia X, Roset M, Herdman M, Kind P,. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making 2001: 21: 7-16.
36. Hongbo Y, Thomas C L, Harrison M A, Salek M S, Finlay A Y,. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005: 125: 659-664.
37. Cvetkovski R S, Zachariae R, Jensen H, Olsen J, Johansen J D, Agner T,. Quality of life and depression in a population of occupational hand eczema patients. Contact Dermatitis 2006: 54: 106-111.
38. Lan C C, Feng W W, Lu Y W, et al. Hand eczema among University Hospital nursing staff: identification of high-risk sector and impact on quality of life. Contact Dermatitis 2008: 59: 301-306.